Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 4067

Project Team

Project lead Vonda Murray

Email enquiries

External Assessment Group School of Health and Related Research (ScHARR), University of Sheffield

Stakeholders

Companies sponsors Sanofi
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Blood Cancer UK
  Myeloma UK
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists
  UK Myeloma Society
Associated public health groups None
Comparator companies Advanz Pharma (dexamethasone, lenalidomide) confidentiality agreement not signed, not participating
  Aspen (dexamethasone) confidentiality agreement not signed, not participating
  Aspire Pharma (dexamethasone) confidentiality agreement not signed, not participating
  Bristol Myers Squibb (lenalidomide, pomalidomide) confidentiality agreement not signed, not participating
  Cipla (lenalidomide) confidentiality agreement not signed, not participating
  GlaxoSmithKline (belantamab mafodotin) confidentiality agreement not signed, not participating
  Glenmark Pharmaceuticals (dexamethasone) confidentiality agreement not signed, not participating
  hameln pharma (dexamethasone) confidentiality agreement not signed, not participating
  Hospira (dexamethasone) confidentiality agreement not signed, not participating
  Janssen-Cilag (ciltacabtagene autoleucel, daratumumab) confidentiality agreement not signed, not participating
  Laboratoires CTRS (dexamethasone) – confidentiality agreement not signed, not participating
  Martindale Pharma (dexamethasone) – confidentiality agreement not signed, not participating
  Mylan (lenalidomide) – confidentiality agreement not signed, not participating
  Noridem Enterprises (dexamethasone) – confidentiality agreement not signed, not participating
  Panpharma (dexamethasone) – confidentiality agreement not signed, not participating
  Pfizer (elranatamab) – confidentiality agreement not signed, not participating
  Piramal Critical Care (lenalidomide) – confidentiality agreement not signed, not participating
  Ranbaxy (lenalidomide) – confidentiality agreement not signed, not participating
  Rosemont Pharmaceuticals (dexamethasone) – confidentiality agreement not signed, not participating
  Sandoz (lenalidomide) – confidentiality agreement not signed, not participating
  Synchrony Pharma (dexamethasone) – confidentiality agreement not signed, not participating
  Takeda (ixazomib) – confidentiality agreement not signed, not participating
  Teva (lenalidomide) – confidentiality agreement not signed, not participating
  Thame Laboratories (dexamethasone) – confidentiality agreement not signed, not participating
  Thornton & Ross (lenalidomide) – confidentiality agreement not signed, not participating
  Wockhardt (dexamethasone) – confidentiality agreement not signed, not participating
  Zentiva (lenalidomide) – confidentiality agreement not signed, not participating
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Health Technology Wales (HTW)
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research
  National Institute for Health Research

Timeline

Key events during the development of the guidance:

Date Update
17 July 2024 Appeal
20 June 2024 - 04 July 2024 Final draft guidance
14 March 2024 Committee meeting: 2
09 February 2024 - 01 March 2024 Draft guidance
17 January 2024 Committee meeting: 1
03 February 2023 Invitation to participate
06 April 2022 Awaiting development. Status change linked to Topic Selection Decision being set to Selected
06 April 2022 In progress. Review of TA658

For further information on our processes and methods, please see our CHTE processes and methods manual